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Abstract
Background: Thyroid hormones (TH) regulate cholesterol metabolism but their use as lipid-lowering drugs is
restricted due to negative cardiac effects. TH mimetic compounds modulating TH receptor β (THRβ) have been
designed as potential drugs, reducing serum cholesterol levels while avoiding apparent deleterious cardiac effects.
Objective: Using ApoE deficient mice, we examined whether KB3495, a TH mimetic compound, reduces
atherosclerosis and if there is a synergistic effect with atorvastatin. The effect of KB3495 was investigated after 10
and 25 weeks.
Results: KB3495 treatment reduced atherosclerotic plaque formation in aorta and decreased the cholesteryl ester
(CE) content by 57%. Treatment with KB3495 was also associated with a reduction of macrophage content in the
atherosclerotic plaques and reduced serum levels of IL-1β, TNFalpha, IL-6, Interferon γ, MCP-1 and M-CSF. Serum
lipoprotein analysis showed no change in total cholesterol levels in ApoB-containing lipoproteins. KB3495 alone
increased fecal BA excretion by 90%. The excretion of neutral sterols increased in all groups, with the largest
increase in the combination group (350%). After 25 weeks, the animals treated with KB3495 showed 50% lower CE
levels in the skin and even further reductions were observed in the combination group where the CE levels were
reduced by almost 95% as compared to controls.
Conclusion: KB3495 treatment reduced atherosclerosis independently of total cholesterol levels in ApoB-containing
lipoproteins likely by stimulation of sterol excretion from the body and by inhibition of the inflammatory response.
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Introduction
The first-choice treatment to decrease low density lipoprotein
cholesterol (LDL-C) and reduce the risk for atherosclerosis are
3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase
inhibitors (statins) [1]. Statins lower hepatic cholesterol levels
and thereby activate sterol regulatory element binding protein 2
(SREBP2) which in turn induce the expression of the LDL
receptor (LDLR) resulting in increased LDL-C uptake from
plasma. Newer drugs like ezetimibe, which acts by blocking
intestinal cholesterol uptake, have recently been proposed as
complements to statin therapy. Despite these new therapeutic
approaches there still is a demand for improved treatment
strategies. An approach currently widely debated is the
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enhancement of reverse cholesterol transport (RCT)[2], leading
to an increased efflux of cholesterol from peripheral tissues and
to a final excretion of cholesterol in the feces.
Thyroid hormone (TH) reduces circulating cholesterol levels
[3,4] but the deleterious effects on the skeleton, the muscles
and the heart prevents its use as lipid lowering drug [5,6]. TH
binds to two distinct receptors, TRα and TRβ. TRα regulates
heart rate whereas TRβ is highly expressed in the liver and
plays a major role in regulating cholesterol metabolism [7,8].
More recently, TH mimetic compounds that specifically
modulate TRβ either by selective hepatic uptake and/or by
higher binding affinity to TRβ, have been designed as potential
drugs, one compound has been tested in the clinic [9,10].
These substances have been shown to reduce serum
cholesterol while avoiding apparent side-effects on the heart
[11–13].
The present study investigates the combined effect of
KB3495 [Thyroid Receptor Agonists, PCT: WO/05092317A1] a
preferential TR β ligand, and atorvastatin on atherosclerosis.
We choose to combine a preferential TR β ligand with a
cholesterol synthesis inhibitor in order to detect possible
additive and synergistic effects on cholesterol metabolism and
atherosclerosis. This in light of the possibility to use TR β
modulators as complement to statin therapy. ApoE deficient
mice, an established mouse model for atherosclerosis, were
treated with KB3495 and atorvastatin either alone or in
combination for a period of 10 or 25 weeks. Following KB3495
treatment, atherosclerosis was markedly reduced and the
effect was shown to be independent of total cholesterol levels
in ApoB-containing lipoproteins and associated to a reduction
of inflammatory response. KB3495 together with atorvastatin
also reduced cholesterol synthesis, increased bile acid (BA)
formation and induced excretion of fecal BA and neutral
sterols.
Materials and Methods
Ethics Statement
Studies were approved by the institutional Animal Care and
Use Committee at Stockholms södra djurförsöksetiska nämnd
(Dnr S27-05).
Studies with KB3495
TR-binding affinities were measured as described [14,15].
Briefly, KB3495 (Figure S1) was incubated with [125I]T3 and
recombinant hTRα or –β until equilibrium and unbound ligand
was separated from receptor-bound ligand. IC50 values
represent the concentration of KB3495 inhibiting 50% of the
binding of [125I]T3 (Figure S1).
Animals
Eighty male ApoE-/- mice (Jackson Laboratories) were
challenged with a western like diet containing 10% of calories
as saturated fat and 0.2% cholesterol (w/w) (Harlan
Laboratories). Food and water was given Ad libitum. The
animals were divided into 4 groups, control group, KB3495
group receiving diet supplemented with 0.7 mg/kg (w/w) of
KB3495, atorvastatin group receiving diet supplemented with
110 mg/kg (w/w) of atorvastatin and the combination group
receiving diet supplemented with 0.7 mg/kg (w/w) of KB3495
and 110 mg/kg (w/w) of atorvastatin, corresponding to a total
daily dose of approximately 3.5 µg KB3495 and 550 µg
atorvastatin.
Half of the animals in each group were sacrificed after 10
weeks and the rest following 25 weeks of treatment. Mice were
fasted for 4 hours prior sacrifice. Blood was drawn by cardiac
puncture under carbon dioxide anesthesia. Livers and
intestines were frozen in liquid nitrogen. Skin and aorta were
frozen in liquid nitrogen or alternatively stored in formalin.
Feces were collected group-wise the last 48 h of the
experiment in which the animals were sacrificed after 10 weeks
treatment (10 w).
Histological investigation
Aortas from 6 animals in the control group (25 w) and 9
animals in the KB3495 group (25 w) were cryo-sectioned and
stained for hematoxylin/eosin and oil red-O. Macrophages were
detected using a Mac 1antibody (Pharmingen, BD). The
samples were incubated with HRP labeled EnVision-rabbit
(Dako) before counterstaining with hematoxylin. A plaque index
was calculated by dividing the plaque area with the aorta
circumference.
Skin biopsies from 5 animals in the control and KB3495
group and 4 animals in the atorvastatin and combination group
were collected after 25 weeks of treatment. Skin was paraffin
embedded and thickness of dermis and epidermis was
measured. Macrophages were detected using a Mac3 antibody
and the percentage of dermis and epidermis covered with
macrophages was determined.
All areas were calculated by using Leica Q500, an image
analysis system. The histological investigation was done by
MicroMorph Histology Services, Lund, Sweden.
Lipid Analysis
Size exclusion chromatography of serum lipoproteins from
each individual mouse was performed according to Parini et al.
[16]. Lipids from aorta, liver and skin from individual animals
were extracted in chloroform/methanol [17]. Total and free
cholesterol levels were determined by isotope dilution-mass
spectrometry according to Björkhem I et al. [18] with some
modifications, see supplements for details.
Lathosterols were analyzed according to Lund et al. [19].
After lipid extraction remaining tissue was dissolved in 1N
NaOH for protein determination.
Cytokine and Chemokime Analysis
Cytokines and chemokine in serum were measured using the
Milliplex ® MAP Mouse Cytokine/Chemokine Magnetic
Premixed Bead panel Immunoassay (Millipore) according to
the manufacturer’s instructions.
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Isolation of Hepatic Membranes and Analysis of Protein
Expression
Hepatic membranes of individual animals were isolated and
ABCA1, LDLR and SR-B1 protein levels were quantified with
western blot, see supplementary data for a detailed protocol.
Quantification of protein expression was done by titration of the
loaded samples. By this approach, the slope of the curve
describing the regression between the luminescence signal
and the amount of protein loaded reflects the concentration of
the protein of interest.
Isolation of Hepatic Microsomes and ACAT activity
Liver microsomes from individual animals were isolated and
ACAT1 and ACAT2 activity was determined as described
previously [20].
Gene Expression.  RNA from individual animals was
extracted with Trizol reagent (Invitrogen). cDNA synthesis was
performed using MultiScribe Reverse Transcriptase (Applied
Biosystems). Quantitative real-time PCR was performed with
SYBR Green assay on an ABI Prism 7000 instrument (Applied
Biosystems). As endogenous control the mean value of
cyclophilin and GAPDH was used. Primers span over exon-
exon junction, sequences are available on request.
Bile Acid analysis
Feces were analyzed for neutral sterols and BAs according
to Miettinen et al. and Grundy et al. [21,22] with some
modifications. Most importantly, no column chromatography
was used prior to gas chromatography.
Statistics
Data are presented as means ± SEM. The significance of
differences between groups was tested by ANOVA followed by
post-hoc comparisons of group means according to the LSD
method (Statistica software, Stat Soft Inc.). Contrasts between
two groups were performed according to Student’s t test. Data
were log-transformed when the assumptions of
homoscedasticity and no correlation between means and
variances were not met [23].
Results
Atherosclerosis development
In order to evaluate the effects of long term treatment with
the preferential TR β ligand KB3495 alone or in association
with atorvastatin on the development of atherosclerosis ApoE
deficient mice were treated for 10 or 25 weeks. After 10 weeks
of treatment, 50% of the animals in each group were sacrificed
and aortas collected. Atherosclerosis was measured by
determination of lipid content in accordance to Rudel LL at al.
[24]. Cholesteryl ester (CE) levels in the aortas were
approximately 60% lower in the group receiving KB3495 (p<
0.01; Figure 1A) as compared to the control group. A tendency
to reduced CE levels in the combination group (KB3495 +
atorvastatin) was observed. When all the data relative animals
treated with a specific treatment were analysed by 2-way
ANOVA, it was clear that KB3495 significantly reduced the CE
content in aorta. The effect was independent of the presence or
absence of atorvastatin. Atorvastatin had no effect. Free
cholesterol (FC) levels remained stable.
Next, we investigated the effects of the maintenance of the
treatments for 25 weeks. Following 25 weeks CE levels in the
aorta were reduced by 65% (p<0.05; Figure 1B) in the
combination group. There was a trend towards reduced levels
also in the KB3495 and the atorvastatin group; however this did
not reach statistical significance using 1-way ANOVA.
Nevertheless, KB3495 lowered the levels of CE in aorta
(p<0.05) independently of the presence or absence of
atorvastatin when the data were analyzed by 2-way ANOVA.
To investigate if atherosclerosis measured as CE content in
the whole aorta corresponded to plaque size, aortic valves from
KB3495-treated and control animals underwent histological
examination and oil red-O staining (Figure 1C). The plaque
index was reduced by 53% in KB3495 animals compared to
controls (0.06 ± 0.01 vs. 0.13 ± 0.01; p< 0.05) and the
percentage of oil red-O staining in the plaques was reduced by
35% (20.7% ± 3.69 vs. 13.4% ± 1.38; p<0.005).
Staining also revealed that KB3495-treated animals had a
lower percentage of macrophages in the plaques (p<0.05;
Table 1).
Serum lipoproteins
In order to investigate if the observed reduction in the
atherosclerotic lesions could be explained by lower levels of
circulating cholesterol the serum lipoproteins were analysed.
After 10 weeks of treatment, total serum cholesterol was not
affected by KB3495 treatment alone but a minor decrease was
detected in the combination group (p< 0.05; Table 2). After 25
weeks no difference between the groups could be detected. To
investigate the lipoproteins in detail, the lipoprotein profiles
were analyzed by SEC. In ApoE deficient mice lipoproteins
consist mainly of chylomicron remnants (CR) of intestinal origin
[25]. These particles separate within the size/density interval
typical of VLDL and LDL particles making it impossible to
isolate pure CR, VLDL and LDL fractions. Hence, we refer to
these particles as ApoB-containing particles (intestinal and
hepatic). See Table 2 and Figures S2 and S3 for lipoprotein
profiles.
After 10 weeks of treatment no major effects on TC levels in
ApoB-containing particles were observed, only a small
decrease in the combination group was detected. FC and TG
increased in the ApoB-containing particles in mice receiving
KB3495 alone, whereas the levels remained unchanged in the
animals receiving atorvastatin alone or in combination with
KB3495. Analysis of PL in the particles showed no difference
between the groups.
Following 25 weeks of treatment the TC levels in ApoB-
containing lipoproteins were still not changed following KB3495
treatment and remained unchanged also following the other
treatments. FC levels remained unchanged in the animals
receiving KB3495 but were increased in mice receiving
atorvastatin. Analysis of TG content in the lipoproteins revealed
an increase in the atorvastatin and combination groups.
Analysis of PL showed lower lipoprotein levels in all treatment-
groups compared to controls.
KB3495 and Atherosclerosis in Mice
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Figure 1.  Cholesterol content in aorta.  (A) Free cholesterol and cholesteryl ester content in the aorta from mice treated for 10
weeks, n=10 in control and KB group, n= 9 in Atorvastatin group and combination group. (B) Free cholesterol and cholesteryl ester
content in the aorta from mice treated for 25 weeks, n=6 in controls, n=7 in KB group, n= 8 in Atorvastatin group and combination
group. Values in (A) and (B) are corrected for protein levels and show mean ± SEM. (C) Hematoxylin/eosin (1,3) and oil red staining
(2,4) of aorta from one control animal treated for 25 weeks (1, 2) and one animal treated with KB3495 for 25 weeks (3, 4). pl
indicates plaque formation, sv indicates semilunar valves. Scalebar in 2 represents 300 μm and is valid for 1-4.
doi: 10.1371/journal.pone.0078534.g001
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Serum granulocytes and monocytes differentiation
factors and inflammatory cytokines
Since treatment with KB3495 and atorvastatin was
associated with reduced numbers of macrophages in the
atherosclerotic lesions we decided to investigate whether this
effect was also associated with an improved inflammatory
profile. We focused the analysis in animals treated for 10
weeks as the longer treatment (25 weeks) was associated with
skin wounds thus limiting the physiopathological relevance of
cytokine and chemokine analysis at this time point.
First, factors stimulating stem cells to differentiate into
granulocytes and monocytes from the bone marrow, such as
Granulocyte-macrophage colony-stimulating factor (GM-CSF),
Granulocyte colony-stimulating factor (G-CSF) and
Macrophage colony-stimulating factor (M-CSF) were studied.
Treatment with KB3495, atorvastatin or the combination
resulted in a significant reduction of M-CSF compared to
controls (Figure 2A). Similarly the levels of G-CSF were
reduced by KB3495 treatment whereas the levels of GM-CSF
slightly increased respectively (Table S1 in File S1).
Atorvastatin alone or in combination with KB3495 had opposite
effects on GM-CSF and G-CSF (Table S1 in File S1). Next we
analyzed chemokines that support the recruitment of
Table 1. Macrophage staining (%) in aorta and dermis after
25 weeks of treatment.
 Aorta Dermis
Ctrl 48.4±2.2 (6) 22.6±3.1 (5)
KB 40.7±2.5* (9) 8±1** (5)
Atorva Not measured 10.9±4.3** (4)
Comb. Not measured No detection (4)
Ctrl: controls; KB: treatment with KB3495; Atorva: treatment with atorvastatin;
Comb.: treatment with KB3495 and atorvastatin in combination. (n): numbers of
animals analyzed. Mean values ± SEM, contrast vs. Ctrl: *= p<0.05; ** = p < 0.01;
*** = p < 0.001.
doi: 10.1371/journal.pone.0078534.t001
monocytes into the atherosclerotic plaques. Treatment with
KB3495 alone significantly reduced serum levels of monocyte
chemotactic protein-1 (MCP-1), involved in the chemokine
receptor CCR2 mediated recruitment (Figure 2B), while the
chemokines involved in the CCR5 mediated recruitment, such
as Rantes or MIP-1α were either slightly increased or not
affected, respectively (Table S1 in File S1). Atorvastatin
treatment resulted in the induction of MCP-1 and MIP-1α and a
reduction in Rantes expression (Figure 2B and Table S1 in File
S1). To finally investigate whether macrophage reduction
following KB3495 treatment could be associated with an
improved immune-inflammatory status, additional markers of
the inflammatory status were characterized. Treatment with
KB3495 resulted in a significant reduction of IL-1beta, IL-6,
TNF alpha and Interferon γ (Figure 2B). The combination of
KB3495 with atorvastatin did not result in any additional benefit
on the profile of these cytokines (Figure 2B).
Hepatic expression of ABCA1 and SR-B1
After 10 weeks of treatment the protein expression of ABCA1
was increased in KB3495 treated animals compared to
controls, the atorvastatin and the combination groups had a
lower expression compared to controls (Figure S4A). The
mRNA expression was 21% (p<0.01; Table 3) lower in the
KB3495 group and 35% (p<0.001; Table 3) lower in the
combination group. After 25 weeks ABCA1 protein expression
was slightly reduced following KB and combination treatment
(Figure S4B), mRNA expression was unchanged (Table 3).
Protein expression of SR-B1 was not changed in the KB3495
group, neither after 10 nor after 25 weeks. The atorvastatin
group showed decreased protein expression following both 10
and 25 weeks. The combination group showed reduced protein
expression of SRB1 after 10 weeks, after 25 weeks only minor
reductions could be seen (Figures S4A and S4B). The mRNA
levels of Sr-b1 were not changed in either group neither after
10 nor 25 weeks (Table 3).
Table 2. Serum lipoproteins from animals treated 10 and 25 weeks.
  Total Free Triglycerides Phospholipids
  cholesterol Cholesterol   
  Total AB Total AB Total AB Total AB
10 weeks Ctrl 13.78 13.35 4.46 4.46 0.88 0.74 13.50 13.49
 KB 14.82 14.27 5.93* 5.92* 1.22 1.14* 15.08 15.06
 Atorva 11.74 11.21 4.02 4.02 0.56 0.46 14.90 14.89
 Comb. 11.15* 10.70* 4.20 4.19 0.72 0.62 12.03 12.02
25 weeks Ctrl 16.39 16.38 8.67 7.99 2.84 2.80 8.17 7.11
 KB 14.96 14.96 9.63 8.78 3.47 3.44 5.19*** 4.40***
 Atorva 18.17 18.17 12.00*** 11.18*** 8.21*** 8.15*** 5.85** 5.33*
 Comb. 17.06 17.05 8.91 8.31 5.06* 5.01* 3.95*** 3.47***
AB: apolipoprotein B-containing lipoproteins. Ctrl: controls; KB: treatment with KB3495; Atorva: treatment with atorvastatin; Comb.: treatment with KB3495 and atorvastatin
in combination. Data is expressed in mmol/L, mean values are shown. In animals treated for 10 weeks n= 10 per group, in animals treated for 25 weeks n=7 in controls,
n=10 in KB group, n= 9 in Atorvastatin group, n= 8 in combination group. Contrast vs. Ctrl * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
doi: 10.1371/journal.pone.0078534.t002
KB3495 and Atherosclerosis in Mice
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e78534
Figure 2.  Serum profiling of granulocyte and monocyte
differentiation factors and of chemokines and
cytokines.  Granulocytes and monocytes differentiation
factors, cytokines and chemokines measured in sera, n=5 per
group. Data show mean ± SEM for the control group. Panel 2A
presents the data for granulocyte-macrophage colony-
stimulating factor (GM-CSF). Panel 2B presents the data for
monocyte chemoattractant protein 1 (MCP-1), interleukin
(IL)-1beta, IL-6, tumor necrosis factor (TNF) alpha and
interferon γ.
doi: 10.1371/journal.pone.0078534.g002
Cholesterol synthesis, transport and excretion
Since lower serum cholesterol was not the cause of the
reduced atherosclerosis observed in the KB3495-treated
animals we investigated if the synthesis, storage and excretion
of cholesterol was affected by KB3495. Hepatic lathosterol
levels were reduced by approximately 50% in the KB3495 and
the combination group following both 10 (p< 0.001; Figure 3A)
and 25 (p< 0.01; p< 0.05; Figure 3B) weeks of treatment,
indicating a reduced cholesterol synthesis.
After 10 weeks the hepatic CE content was reduced
following KB3495 (-34%; p< 0.05) and combination (-59%; p<
0.001) treatment; whereas no differences were observed in FC
levels (Figure 3C). Following 25 weeks CE levels in the liver
did not show the same pattern as after 10 weeks of treatment.
A trend towards reduced levels in the KB3495 group was
present, however a statistically significant reduction was only
observed in the atorvastatin (p<0.05) and combination groups
(p<0.01; Figure 3D).
To investigate the mechanisms behind the changed
cholesterol levels in livers, protein and mRNA levels of key
genes involved in hepatic cholesterol metabolism were
determined. See Table 3 for mRNA results. Following 10
weeks of treatment protein expression for LDLR was
decreased in the KB3495 group, this however was not
paralleled by similar changes in mRNA expression (Figure
S4A; and Table 3). The mRNA expression of Hmgr was
increased (220%; p< 0.001) in the combination group. Hepatic
gene expression of Pcsk9 did not show any significant changes
and had an expression pattern almost identical to that seen for
Ldlr. Gene expression of Abcg5 was decreased to 70% (p<
0.01) of controls following KB3495 treatment, no changes was
observed in Abcg8 expression in the KB3495 group. However,
Abcg8 levels were increased to approximately 160% (p< 0.01
resp. 0.001) in the atorvastatin and combination groups. The
mRNA levels of triglyceride hydrolase (Tgh) 1 and Tgh2 were
not altered by KB3495 but were reduced by approximately 80%
and 70% respectively following statin and the combination
treatment (p< 0.001). The transcription factor Srebp1c was
decreased to about 50% in all three groups compared to
controls (p< 0.05 for single treatments and p< 0.001 for
combination). Srebp2 levels were increased (134%; p< 0.01) in
the combination group but remained stable in the other groups.
The mRNA level of Soat2 was not changed by either treatment
nor was the ACAT2 activity (Figure S5; Table 3).
Following 25 weeks of treatment mRNA levels of Ldlr was
increased to 142% (p<0.05) in the KB3495 group whereas no
change was observed in the atorvastatin and combination
group. In contrast, Pcsk9 expression was markedly
upregulated following atorvastatin (320%; p<0.05) and
combination treatment (998%; p<0.001). No changes were
observed in the KB3495 group. Despite the high expression of
Pcsk9 the protein level of LDLR was increased following
atorvastatin (171%) and combination treatment (134%; Figure
S4B). The mRNA expression of Hmgr was increased following
atorvastatin (154%; p< 0.05) and combination (213%; p<
0.001) treatment. Gene expression of Abcg5 and Abcg8 were
not changed from 10 to 25 weeks. mRNA levels of Tgh1 and
KB3495 and Atherosclerosis in Mice
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e78534
Tgh2 were still reduced by atorvastatin but after 25 weeks
there was no longer any reduction in the combination group,
After 10 weeks of treatment the fecal excretion of neutral
sterols was increased in all groups compared to controls, the
largest increase was observed in the combination group
(350%; Figure 4A).
BA synthesis, transport and excretion
In order to assess the conversion of cholesterol into BAs we
determined the fecal BA excretion. Following 10 weeks of
treatment BA excretion was increased by approximately 90% in
the KB3495 group compared to controls indicating an
increased BA synthesis. Addition of atorvastatin somewhat
reduced the effects of KB3495 (Figure 4B). Next, hepatic
mRNA expressions for key genes in BA synthesis and
transport (10 weeks) were analyzed (Table 3). Expression of
Cyp7a1, the rate limiting enzyme in the neutral pathway of BA
synthesis, increased by 78 % (p< 0.05) following atorvastatin
treatment and by 204 % (p< 0.001) after combination
treatment. Expression of Cyp8b1, Cyp27a1 and Shp was not
changed by KB3495 treatment, whereas an almost 50%
decrease in Cyp8b1 (p<0.01) was observed in the atorvastatin
group. Recently, FGF15 has been identified as an ileal growth
factor involved in the feedback regulation of BA synthesis in the
liver [26]. Thus, the expression of Fgf15 in the ileum was
determined. KB3495 alone, or in association with atorvastatin,
decreased the mRNA levels to 11% (p<0.001).
Unfortunately no feces were collected following 25 weeks of
treatment which make it difficult to quantify BA synthesis. After
25 weeks the mRNA expression of CYP7A1 was no longer
significantly changed, neither was the expression of FGF15
although there was a tendency to reduced FGF15 expression
following KB and combination treatment (Table 3).
Hepatic triglycerides
Following 10 weeks of treatment hepatic TG levels were not
changed by KB3495 but were lowered by statin and
combination treatment (p< 0.001 resp. p< 0.01; Figure 3E).
After 25 weeks TG levels were increased following KB3495
(p<0.001) and combination treatment (p<0.01; Figure 3F).
Skin lipid content after 25 weeks of treatment
After 25 weeks of a western like diet the skin of the control
group appeared thickened and the fur was sparse and in poor
condition which was in sharp contrast to the group receiving
KB3495 where the fur was glossy and shiny. Therefore skin
samples were collected and CE levels were analyzed. In
animals receiving KB3495 CE levels were reduced by
approximately 50% (p<0.01; Figure 5A), even further
reductions were observed in the combination group where the
levels were reduced by almost 95% (p<0.01; Figure 5A).
Histological analysis revealed that KB3495 had reduced skin
thickness (Figure 5B) and a lower percentage of positive
staining for macrophages (p<0.001; Table 1).
Discussion
In this study we investigated the long term effects of KB3495
on the development of atherosclerosis. Using ApoE deficient
animals we show that atherosclerosis is reduced following
treatment with KB3495. Here we demonstrate for the first time
that the anti-atherosclerotic effects are independent of the
Table 3. Hepatic mRNA expression after 10 and 25 weeks of treatment.
 10 weeks 25 weeks
 Ctrl KB Atorva Comb. Ctrl KB Atorva Comb.
Abca1 100±7 79±4** 88±3 65±4*** 100 88 69 94
Abcg5 100±10 70±6** 123±7 115±5 100±8 74±7* 137±3* 114±4
Abcg8 Acat2 100±10 100 96±8 126 156±13** 110 165±11***115 100±9 100 96±7 68 187±12***126 160±15** 141
Cyp27a1 100±14 99±5 105±4 112±7 100±12 80±7 90±7 104±9
Cyp7a1 100±14 104±13 178±23* 304±36*** 100±24 97±11 111±39 121±19
Cyp8b1 100±9 115±13 59±7** 64±8** 100±11 107±15 68±10 68±7
Fgf15# 100±20 11±4*** 177±26*** 11±5*** 100±44 41±13 114±41 45±12
Hmgr 100±14 79±11 82±16 226±35*** 100±11 127±11 154±21* 213±31***
LdlR 100±8 86±5 83±4* 112±5 100±19 142±9* 97±8 126±8
Pcsk9 100±8 86±10 77±10 121±9 100±11 170±55 320±109* 998±299***
Shp 100 105 90 80 100 95 61 85
Srb1 100±11 90±4 87±4 82±5 100 76 70 72
Srebp1c 100±17 54±7* 64±12* 38±6*** 100±34 139±19 78±12 109±20
Srebp2 100±5 99±5 107±5 134±11** 100±4 125±12 139±10* 175±19***
Tgh1 100±9 121±14 23±3*** 29±3*** 100±35 146±13 72±11 166±33
Tgh2 100±9 117±13 10±2*** 16±2*** 100±31 183±26 29±7** 217±93
Mean values expressed as percent of control ± SEM. In animals treated for 10 weeks n= 10 per group, in animals treated for 25 weeks n=7 in controls, n=9 in the other
groups.* = p < 0.05; ** = p < 0.01; *** = p < 0.001. In case of no SEM, only pooled data is analyzed.
#. mRNA from intestine.
doi: 10.1371/journal.pone.0078534.t003
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levels of cholesterol in ApoB-containing lipoproteins. In a
previous study where ApoE deficient animals were treated with
the thyromimetic compound T-0681 cholesterol levels were
reduced in these lipoproteins [27]. We decided to treat animals
for 10 and 25 weeks to see whether the effects attributed to
thyromimetic compounds would still be present after long term
treatment (10 and 25 weeks).
After 10 weeks of treatment CE levels in aorta were reduced
by 50% after KB3495 treatment, following 25 weeks it appears
that KB3495 could exert its positive action also in combination
with atorvastatin, causing a reduction by 65%. Histochemical
analyses of the aortic valves, confirmed the reduction in
atherosclerosis. The positive effects of KB3495 after 25 week
treatment on atherosclerosis were only evident in the 2-way
ANOVA analysis. This was the consequence of a greater
variability for CE content observed in the control mice.
Treatment with KB3495 was also associated with a reduction of
macrophage content in the atherosclerotic plaques and
reduced serum levels of IL-1β, TNFalpha, IL-6, Interferon γ,
MCP-1 and M-CSF. Interestingly, KB3495 did not only
positively affect the cytokines responsible for the maturation
and recruitment of monocyte/macrophages in the
atherosclerotic plaques but it also attenuated the perpetuation
of the inflammatory response.
Similarly, a reduction of CE in the skin was observed
following treatment with KB3495; this reduction was even more
prominent in combination with atorvastatin. This dramatic effect
on cholesterol deposition in aortas and skin, independent of TC
levels in ApoB-containing lipoproteins is remarkable and we
are currently addressing the molecular mechanisms behind this
effect. Cholesterol accumulation and increased inflammation in
the skin of ApoE deficient mice have been reported previously
[28,29]. One suggested explanation is an altered migration of
dendritic cells in the skin [30]. ApoE deficient mice have an
impaired migration of dendritic cells to lymph nodes as
compared to wild-type mice and the dendritic cells remaining in
epidermis appeared to be activated causing dermal thickening
and inflammation. According to studies in LDLr-/- and ApoA-1-/-
mice there seems to be a connection between mobilization of
skin dentritic cells and cholesterol homeostasis [31].
Since KB3495 treatment affects the cholesterol content in
both aorta and skin independently of major lipoprotein
Figure 3.  Lipid content in the liver.  (A) Lathosterol content in the liver from animals treated for 10 weeks, n=10 per group. (B)
Lathosterol content in the liver from animals treated for 25 weeks, n=7 in controls, n=9 in the other groups. (C) Free cholesterol and
cholesteryl ester content in liver from animals treated for 10 weeks, n=10 per group. (D) Free cholesterol and cholesteryl ester
content in liver from animals treated for 25 weeks, n=7 in controls, n=9 in the other groups. (E) Triglyceride content in liver from
animals treated for 10 weeks, n=10 per group. (F) Triglyceride content in liver from animals treated for 25 weeks, n=7 in controls,
n=9 in the other groups. All data are corrected for protein content and show mean ± SEM.
doi: 10.1371/journal.pone.0078534.g003
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changes, we investigated whether the substance may have
enhanced the hepatic cholesterol metabolism. Following both
KB3495 and combination treatment, a reduction of hepatic
lathosterol content, indicating a reduced hepatic cholesterol
synthesis [32] was observed. This was independent of the
duration of the treatments and the effects on hepatic
cholesterol synthesis were not paralleled by changes in the
hepatic expression of the rate-limiting enzyme Hmgr. Similar
results was also observed with the TRβ modulator GC-1 [33].
The discrepancy observed between hepatic cholesterol
synthesis and Hmgr gene expression is nevertheless in line
Figure 4.  Fecal excretion.  (A) Fecal excretion of neutral sterols from animals treated for 10 weeks, feces was collected group
wise (pooled) for 48h, n=10 per group. (B) Fecal excretion of bile acids from animals treated for 10 weeks, feces was collected
group wise (pooled) for 48h, n=10 per group.
doi: 10.1371/journal.pone.0078534.g004
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with the known post transcriptional regulation of this gene, a
topic reviewed by Ness et al. [34].
Earlier studies with selective TR mimetics showed reduced
levels of circulating LDL cholesterol and the suggested
mechanism is an increased expression of LDLR. T3 and TR
mimetics have been shown to increase the expression of LDLR
in hypophysectomized and intact rats [35,36]. Furthermore, in
diet induced obese mice, the Ldlr expression has been shown
to increase following the administration of T3 and MB07811,
however, this effect was transient being visible only at 3 hours
and 8 hours after administration and absent after 24 hours [37].
However, the TRβ modulators GC-1 and T-0681 failed to
upregulate Ldlr in hypercholesterolemic mice [33] and in
C57BL/6 or ApoE-/- mice [27], respectively. Thus, the lack of
Figure 5.  Lipid content in the skin.  (A) Free cholesterol and cholesteryl ester content in the skin, data are corrected for protein
levels and show mean ± SEM. n=7 in controls, n=9 in KB group, n= 9 in atorvastatin group, n=8 combination group. (B) Histological
staining of skin with the specific macrophage Mac-3 marker. ED indicates epidermis, D indicates dermis. 1: control, 2: KB3495, 3:
atorvastatin, 4: combination of KB3495 and atorvastatin.
doi: 10.1371/journal.pone.0078534.g005
KB3495 and Atherosclerosis in Mice
PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e78534
stimulation of Ldlr by long-term treatment with KB3495 is not
surprising.
One way to decrease cholesterol accumulation is by
stimulation of RCT. This complex process which transfers
cholesterol from peripheral cells to the liver for subsequent
elimination as BAs and neutral steroids was originally proposed
by Glomset more than 40 years ago [38]. Following treatment
with KB3495 alone or in combination with atorvastatin, the fecal
excretion of neutral sterols increased by approximately 60%
and 350%, respectively, demonstrating a net efflux of
cholesterol from the body. Previously, the biliary secretion of
cholesterol has been shown to be increased in hypothyroid rats
upon TH administration [39]. This was later explained by the
induction of Abcg5 and Abcg8 following T4 substitution [40].
However, we did not observe any increase in the hepatic
expression of Abcg5 and Abcg8 following KB3495 treatment.
Nevertheless, the fecal excretion of neutral sterols was highly
induced by KB3495 especially in combination with atorvastatin.
Cholesterol can be excreted in the feces independently of the
biliary output. ABCG5/G8 knockout mice, which have extremely
low concentrations of biliary cholesterol, show a relatively
modest reduction in fecal neutral sterols [41]. Furthermore,
after LXR induction or hepatic ACAT2 depletion an increase in
fecal neutral sterol excretion was observed independently of
the biliary cholesterol secretion [42,43]. The above
observations can be explained by the newly described trans
intestinal cholesterol excretion (TICE) in which enterocytes
contribute to fecal neutral sterols by a direct secretion of
cholesterol [44]. This study was designed and performed prior
the description of TICE and biliary cholesterol secretion rates
were unfortunately not measured.
In order to assess the conversion of cholesterol into BAs, we
determined the fecal BA excretion. KB3495 caused a strong
increase in BA synthesis, an effect that was in part reduced by
addition of atorvastatin, which instead increased the neutral
sterol excretion. Interestingly, the effects on BA synthesis were
not always paralleled by similar changes in hepatic Cyp7a1
expression. Previous studies with TH and other TH mimetics
(GC-1) have clearly shown that Cyp7a1 expression is regulated
by TH in rodents [33,45,46] and a thyroid receptor responsive
element (TRE) has been identified in the promoter region of
this gene [47]. The absence of a clear correlation between
Cyp7a1 expression and fecal BA expression in our
experiments compared to the study with the GC-1 compound
may be due to differences in administration of the drug (orally
vs. i.p.).
Data from this study indicates that KB3495 causes a
reduction in cholesterol synthesis and an increase in BA as
well as neutral sterol excretion without affecting serum
cholesterol levels in ApoE deficient mice. One explanation for
this observation may be that the dyslipidemia of ApoE deficient
mice is mainly due to remnant lipoproteins of intestinal origin
[25]. Hepatic VLDL secretion reduced in these animals [48]. In
ApoE deficient mice, a Western-like diet induces a massive
dyslipidemia and the circulating levels of cholesterol and TGs
mainly reflect the contribution from the intestine. Thus, it is
expected that the inhibition of endogenous cholesterol
synthesis per se is not sufficient to affect the plasma levels of
cholesterol and BAs.
Unlike cholesterol, TG levels were increased following
KB3495 treatment. After 10 weeks there was a slight increase
in serum TG whereas liver TG was unchanged compared to
controls. However, after 25 weeks, serum TG was unchanged
but elevated levels were detected in the liver. In atorvastatin
treated animals on the other hand, there was no increase in
liver TG but serum TG was elevated. Thus, it seems like
KB3495 treatment promotes TG storage while atorvastatin
treatment increases the transport out to the peripheral tissues.
Conclusions
In conclusion, KB3495 reduce atherosclerosis independently
of changes in total cholesterol levels in ApoB-containing
lipoproteins. Cholesterol levels are reduced by multiple ways;
cholesterol synthesis is decreased, formation of BAs, as well
as the excretion of fecal BAs and neutral sterols is induced.
The beneficial effect on atherosclerosis is also paralleled with
decreased inflammation. Whether the reduced inflammation is
the consequence of or is the cause for the reduced
atherosclerosis is still an open question.
Supporting Information
Figure S1.  KB3495. Structure and IC50 of KB3495.
(TIF)
Figure S2.  Serum lipoproteins. Serum lipoproteins from
animals treated for 10 weeks, the mean curve is shown. (A)
Total cholesterol. (B) Free cholesterol. (C) Triglycerides. (D)
Phospholipids.
(TIF)
Figure S3.  Serum lipoproteins. Serum lipoproteins from
animals treated for 25 weeks, the mean curve is shown. (A)
Total cholesterol. (B) Free cholesterol. (C) Triglycerides. (D)
Phospholipids.
(TIF)
Figure S4.  Protein expression. (A) Protein expression of
LDLR, ABCA1 and SRB1 in pooled liver membranes from
animals treated for 10 weeks, n=10 per group. (B) Protein
expression of LDLR, ABCA1 and SRB1 in pooled liver
membranes from animals treated for 25 weeks, n=7 in controls,
n=9 in the other groups. Data are expressed as percent of
control.
(TIF)
Figure S5.  ACAT activity. ACAT activity in liver microsomes
from animals treated for 10 weeks, n=10 per group. Data are
expressed as pmol/min/mg, mean values ± SEM.
(TIF)
File S1.  Supporting Information Methods. Table S1, Serum
concentration of chemokines and cytokines (pg/mL).
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